Compare Alcon AG (ALC) vs Citigroup Inc. (C) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Citigroup Inc. — how do they compare? Alcon AG trades at $66.67 (market cap $32.69B), while Citigroup Inc. trades at $138.02 (market cap $240.09B). The key difference: Citigroup Inc. is far larger — about 7.3× Alcon AG's market cap, and Citigroup Inc. pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| ALC | C | |
|---|---|---|
Market Cap | $32.69B | $240.09B |
Sector | Health | Financials |
52-Week High | $92.22 | $145.67 |
52-Week Low | $62.02 | $85.57 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Citigroup (C) trades at $140.75, up 0.59% today, with a bullish technical outlook and strong analyst support. Recent Q1 2026 earnings beat expectations, and the company expanded its services by joining LPMCL. Revenue and net income have grown steadily, with a P/E of 17.78 and a consensus price target of $151.36. The stock is near its 52-week high, reflecting positive momentum.
The outlook is positive, driven by earnings growth and strategic expansions, but risks include volatile cash flows and high debt levels. Wall Street sentiment is bullish, with 59% of analysts rating it a buy. Investors should weigh the strong fundamentals against macroeconomic and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
